Although it might seem like AI is the newest and hottest innovation in the industry, medical affairs professionals have been using some form of it for decades
To mark upcoming Rare Disease Day, pharmaphorum asked a panel of experts to give their thoughts on the opportunities and challenges facing developers of rare disease therapies in 2024.
When seeking tools for participant retention, payment management, travel, and trial budgeting, considerations for quality may include meeting specific needs.
AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.